Sarepta Therapeutics, Inc. (SRPT)
$
63.82
-6.59 (-10.33%)
Key metrics
Financial statements
Free cash flow per share
-3.5597
Market cap
7 Billion
Price to sales ratio
3.6635
Debt to equity
0.8703
Current ratio
4.2005
Income quality
-0.8748
Average inventory
657.9 Million
ROE
0.1966
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases. The diluted EPS is $2.18 accounting for potential share dilution. The financial data pertains to the fiscal year 2024 reflecting the overall performance of the company. The income before tax ratio is 0.14 which showcases the pre-tax margin and operational efficiency of Sarepta. Furthermore, the cost of revenue for the company is $319,099,000.00 highlighting its production and operational expenses. Despite these costs, the company earned an interest income of $71,767,000.00 showcasing its financial investments and ability to generate additional revenue streams. Sarepta offers the EXONDYS 51 injection and VYONDYS 53 for the treatment of Duchenne muscular dystrophy in patients with specific confirmed mutations in the dystrophin gene. The company is also progressing in developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, thereby solidifying its commitment to addressing rare genetic diseases through innovative therapies. Currently, the stock is reasonably priced at $65.13 appealing to a broad range of investors. This attractiveness is further supported by an average trading volume of 1,367,423.00 indicating moderate liquidity for potential and existing shareholders. With a mid-range market capitalization of $6,192,588,622.00 the company is a steady performer in its sector. It is a key player in the biotechnology industry, contributing significantly to the overall market landscape, while also driving innovation and growth in the healthcare sector. Through its collaborations with multiple organizations, Sarepta continues to enhance its research and development capabilities, positioning itself as a leader in genetic therapies and a vital contributor to advancements aimed at treating rare diseases.
What is Sarepta Therapeutics, Inc. (SRPT)'s stock forecast?
Analysts predict Sarepta Therapeutics, Inc. stock to fluctuate between $62.50 (low) and $173.25 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sarepta Therapeutics, Inc.'s market capitalization?
As of 2025-04-01, Sarepta Therapeutics, Inc.'s market cap is $6,192,588,622, based on 97,032,100 outstanding shares.
How does Sarepta Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sarepta Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sarepta Therapeutics, Inc. (SRPT) stock?
To buy Sarepta Therapeutics, Inc. (SRPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Sarepta Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Sarepta Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,901,979,000 | EPS: $2.47 | Growth: -142.59%.
Where can I find Sarepta Therapeutics, Inc.'s investor relations reports?
Visit https://www.sarepta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sarepta Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sarepta Therapeutics, Inc. stock?
All-time high: $173.25 (2024-06-21) | All-time low: $55.25 (2023-10-31).
What are the key trends affecting Sarepta Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
globenewswire.com
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
zacks.com
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
fool.com
Things are going from bad to worse for Sarepta Therapeutics (SRPT 0.84%), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
seekingalpha.com
Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting a buying opportunity for risk-tolerant investors.
See all news
